Corindus to Showcase CorPath GRX® System for Peripheral Vascular Interventions at the 2018 Amputation Prevention Symposium
Educational Activities will Highlight CorPath GRX Capabilities in PVI procedures
WALTHAM, Mass.--(August 6, 2018)-- Corindus Vascular Robotics, Inc. announced that the CorPath GRX System will be showcased for peripheral applications at the 2018 Amputation Prevention Symposium in Chicago, IL. Jihad Mustapha, M.D., Interventional Cardiologist and AMP course director, will moderate an educational session entitled "Robotic Utilization in CLI in 2018: Protect Your Staff, Protect Yourself" on Friday, August 10th at 4:00 p.m. CT. During this session, Dr. Mustapha will share and discuss a previously taped procedure in which he used the CorPath GRX System during a robotic-assisted critical limb ischemia (CLI) case he performed at the first U.S. outpatient CLI center, the Advanced Cardiac & Vascular Amputation Prevention Center in Grand Rapids, MI, which was opened by Dr. Mustapha and Dr. Fadi Saab in February 2018.
"CorPath GRX offers discrete movements with precise control of interventional devices, offering advanced treatment options for patients suffering from CLI while reducing physician fatigue," said Dr. Jihad Mustapha. "I believe robotics will enable physicians to perform more CLI procedures and will be a critical component to the future treatment paradigm for limb salvage patients. I look forward to educating my peers and the CLI community on my experience with robotic-assisted CLI."
Corindus will feature robotic-assisted peripheral vascular intervention (PVI) in Pavilion B with an opportunity for attendees to experience hands-on demonstrations of the CorPath GRX System with an advanced simulator. During exhibit hours, the Corindus Research and Development team will host a Next-Generation Robotics Showcase in Pavilion B for physicians to participate in development initiatives to capture manual device manipulation data. This data will help support the advancement of current robotic capabilities as well as feed into future technology advancements. AMP attendees are invited to pre-register for a demonstration and the Next-Generation Robotics Showcase by visitingwww.corindus.com/AMP2018.
Corindus received 510(k) clearance for use of its CorPath GRX System in peripheral procedures in February 2018, broadening the capabilities of the CorPath robotic technology platform from exclusively treating coronary artery disease (CAD) to include peripheral artery disease (PAD), a disease of blood vessels outside the heart that commonly affects arteries carrying blood to the lower extremities. Critical limb ischemia (CLI), a form of PAD, is associated with excessively high risk for cardiovascular events, including myocardial infarction, and death. Mortality rates following diagnosis of CLI are as high as 20% after 6 months and 50% after 5 years.1 It is estimated that total hospital costs associated with lower-extremity amputation exceed the cost of revascularization by approximately $10,000.2
About Corindus Vascular Robotics, Inc.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and percutaneous vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.